AxoGen, Inc. (NASDAQ:AXGN) Receives $49.89 Consensus Price Target from Analysts

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $51.00.

Several research analysts have recently weighed in on the company. Canaccord Genuity Group upped their target price on AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Lake Street Capital lifted their price target on shares of AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Citigroup reissued a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Raymond James Financial restated an “outperform” rating and set a $48.00 price objective on shares of AxoGen in a research report on Wednesday, April 29th. Finally, HC Wainwright lifted their target price on shares of AxoGen from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, July 30th.

AxoGen Price Performance

NASDAQ:AXGN opened at $45.22 on Thursday. AxoGen has a 52 week low of $13.46 and a 52 week high of $46.95. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $2.43 billion, a PE ratio of -66.50 and a beta of 1.11. The stock’s 50-day moving average price is $42.42 and its 200-day moving average price is $37.72.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The company had revenue of $69.73 million during the quarter, compared to analysts’ expectations of $67.10 million. As a group, equities analysts expect that AxoGen will post -0.45 EPS for the current fiscal year.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $53 price target for AxoGen (AXGN), suggesting the analyst sees potential upside despite near-term earnings pressure.
• Positive Sentiment: HC Wainwright projects AxoGen will return to profitability in fiscal 2027, with estimated earnings of $0.03 per share, including positive EPS in the third and fourth quarters.
• Neutral Sentiment: Analysts at HC Wainwright reduced estimates across multiple periods: Q3 2026 EPS to a loss of $0.03 from $0.02, Q4 2026 to a loss of $0.04 from $0.04, and Q1 2027 to $0.04 from $0.05.
• Negative Sentiment: The largest revisions were to full-year results. HC Wainwright cut its FY2026 EPS forecast to a loss of $0.46 from $0.32 and reduced FY2027 EPS to $0.03 from $0.44. It also lowered Q2 2027 EPS to a loss of $0.01 from $0.09, Q3 2027 EPS to $0.02 from $0.14, and Q4 2027 EPS to $0.05 from $0.16.
• Negative Sentiment: The revisions imply a slower earnings recovery than previously expected and place HC Wainwright’s FY2026 forecast below the current consensus estimate of a $0.37-per-share loss, weighing on sentiment toward the medical-equipment company.
• Neutral Sentiment: Analysts’ rating outlook remains constructive overall, with AxoGen receiving an average “Moderate Buy” rating. AxoGen Given Average Rating of Moderate Buy by Analysts

Insider Buying and Selling at AxoGen

In related news, Director Amy Mcbride Wendell sold 1,647 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $42.60, for a total value of $70,162.20. Following the transaction, the director directly owned 93,826 shares of the company’s stock, valued at approximately $3,996,987.60. This trade represents a 1.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.44% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AxoGen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. grew its holdings in shares of AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock worth $20,953,000 after buying an additional 1,250,968 shares in the last quarter. Wasatch Advisors LP lifted its stake in shares of AxoGen by 101.1% in the first quarter. Wasatch Advisors LP now owns 1,857,350 shares of the medical equipment provider’s stock worth $61,534,000 after buying an additional 933,778 shares in the last quarter. Millennium Management LLC lifted its stake in shares of AxoGen by 2,255.8% in the fourth quarter. Millennium Management LLC now owns 971,358 shares of the medical equipment provider’s stock worth $31,793,000 after buying an additional 930,126 shares in the last quarter. Next Century Growth Investors LLC acquired a new position in AxoGen during the fourth quarter worth about $26,180,000. Finally, Perceptive Advisors LLC purchased a new stake in AxoGen during the 4th quarter valued at about $25,665,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.